647 related articles for article (PubMed ID: 12042647)
21. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation.
Gridelli B; Spada M; Riva S; Colledan M; Segalin A; Lucianetti A; Sonzogni A; Furione M; Baldanti F; Torre G
Transpl Int; 2000; 13 Suppl 1():S399-401. PubMed ID: 11112041
[TBL] [Abstract][Full Text] [Related]
22. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus load for early detection of lymphoproliferative disorder in pediatric renal transplant recipients.
Ishihara M; Tanaka E; Sato T; Chikamoto H; Hisano M; Akioka Y; Dohno S; Maeda A; Hattori M; Wakiguchi H; Fujieda M
Clin Nephrol; 2011 Jul; 76(1):40-8. PubMed ID: 21722604
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
26. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level.
Orii T; Ohkohchi N; Satomi S; Hoshino Y; Kimura H
Transpl Int; 2002 Nov; 15(11):529-34. PubMed ID: 12461655
[TBL] [Abstract][Full Text] [Related]
27. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy.
Kullberg-Lindh C; Saalman R; Olausson M; Herlenius G; Lindh M
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28039929
[TBL] [Abstract][Full Text] [Related]
29. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR.
Yancoski J; Danielian S; Ibañez J; Turconi A; Cuarterolo M; Zelazko M; Niesters Hubert GM
J Clin Virol; 2004 Sep; 31(1):58-65. PubMed ID: 15288615
[TBL] [Abstract][Full Text] [Related]
30. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.
Green M; Cacciarelli TV; Mazariegos GV; Sigurdsson L; Qu L; Rowe DT; Reyes J
Transplantation; 1998 Dec; 66(12):1641-4. PubMed ID: 9884252
[TBL] [Abstract][Full Text] [Related]
31. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study.
Baudouin V; Dehée A; Pédron-Grossetete B; Ansart-Pirenne H; Haddad E; Maisin A; Loirat C; Sterkers G
Transplantation; 2004 Jun; 77(11):1706-13. PubMed ID: 15201670
[TBL] [Abstract][Full Text] [Related]
32. Seropositivity for cytomegalovirus and PCR-EBV monitoring: Protective factors for posttransplant lymphoproliferative disorder in pediatric liver transplant.
Éboli LPCB; Tannuri ACA; Tannuri U
Pediatr Transplant; 2022 Jun; 26(4):e14226. PubMed ID: 35037358
[TBL] [Abstract][Full Text] [Related]
33. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.
Choquet S; Varnous S; Deback C; Golmard JL; Leblond V
Am J Transplant; 2014 Apr; 14(4):857-66. PubMed ID: 24666832
[TBL] [Abstract][Full Text] [Related]
34. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.
Yang J; Tao Q; Flinn IW; Murray PG; Post LE; Ma H; Piantadosi S; Caligiuri MA; Ambinder RF
Blood; 2000 Dec; 96(13):4055-63. PubMed ID: 11110673
[TBL] [Abstract][Full Text] [Related]
36. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children.
Green M; Bueno J; Rowe D; Mazariegos G; Qu L; Abu-Almagd K; Reyes J
Transplantation; 2000 Aug; 70(4):593-6. PubMed ID: 10972215
[TBL] [Abstract][Full Text] [Related]
37. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience.
Qin T; Gu XQ; Jeong SS; Song YY; Liu JC; Zheng JX; Xue F; Xia Q
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):3-11. PubMed ID: 31932195
[TBL] [Abstract][Full Text] [Related]
38. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
[TBL] [Abstract][Full Text] [Related]
39. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
40. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]